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Use of Distal Protection Device for Percutaneous Intervention in Native
Coronary Arteries
KENNETH KA-HING LAM, SHU-KIN LI
From Cardiology Team, Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong
LAM and LI: Use of Distal Protection Device for Percutaneous Intervention in Native Coronary Arteries.
Microembolization of particulate debris during percutaneous coronary intervention (PCI) will lead to various degree
of microvascular obstruction, terminating in no-reflow phenomenon observed angiographically. Different methods,
including angiography, non-invasive imaging, and assays of myocardial injury markers, have been used for detection
of occurrence of microvascular obstruction. The prevalence of, and the adverse prognosis associated with
microvascular obstruction have led to the concept and application of distal protection for coronary interventions.
While its value has been confirmed in saphenous vein grafts intervention, data is now growing to support use of
distal protection devices in native coronaries. Findings from a local registry that reveals the initial experience on
use of GuardWire Plus System, a kind of occlusive distal protection device, for elective PCI are discussed herein.
(J HK Coll Cardiol 2002;10:191-197)
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Introduction
Microembolization, Microvascular Obstruction
and No-Reflow: Pathophysiology
With the advances seen in various devices used
for percutaneous coronary intervention (PCI) and the
widespread use of stents, acute complications are
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uncommon during the procedure. However, slow distal
flow or no-reflow phenomena remain one of the
frustrations facing interventional cardiologists. The
pathophysiology underlying such phenomena seen
during PCI is likely to be complex, but probably starts
off with microembolization of particulate debris
dislodged from atherosclerotic/thrombotic lesions down
to distal capillary bed, causing microvascular
obstruction. 1 This in turn results in microvascular
plugging, microvascular spasm or edema, and/or platelet
aggregation. Experiments in canine models had shown
that embolization of a coronary artery with minute
particles/microspheres measuring less than 100 µm
resulted in regional contractile dysfunction and
perfusion-contraction mismatch. 2 Following
microvascular obstruction, epicardial flow is initially
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maintained or even enhanced due to an adenosinerelated hyperaemia of the myocardium surrounding the
embolized microregions, with blood shunting around
the areas of microvascular obstruction.1 However, as
the total embolized burdens increase, the epicardial flow
will eventually become reduced, corresponding to the
angiographic manifestation of slow distal flow or noreflow. In other words, no-reflow represents an
advanced stage of significant degree of microvascular
obstruction.

Detection of Microembolization and
Microvascular Obstruction
The presence and extent of microvascular
obstruction can be assessed by examining the degree of
impairment of myocardial perfusion. Several methods
have been used for this purpose. The angiographic
method is perhaps the simplest way in the
catheterization laboratory. Two different approaches
have been derived: first, to record the Corrected TIMI
Frame Count (CTFC) which is defined as the number
of cine frames required for contrast to first reach distal
coronary landmarks in that artery;3 and second, to report
on the TIMI Myocardial Perfusion (TMP) Grades (03) by noting the appearance of blush, and the rate at
which the blush disappears (Figure 1).4 Myocardial
contrast echocardiography constitutes another method

TMP Grade 3
Normal
ground-glass
appearance of
blush. Contrast
mildly persistent at
end of washout

TMP Grade 2
Contrast strongly
persistent at end of
washout. Disappears
by next injection

for assessing myocardial perfusion by intravenous or
intracoronary injection of sonicated bubbles. Ito et al5
showed that myocardial perfusion defects was
detectable in up to 26% of patients who had TIMI 3
flow in the infarct-related artery after reperfusion
therapy (either thrombolysis or primary angioplasty).
Nuclear imaging using Sestamibi Single-Photon
Emission Computerized Tomography (SPECT) has also
been used for detection of myocardial perfusion defects.
Koch et al6 demonstrated that up to 87% of patients
undergoing rotational atherectomy had detectable
perfusion defects on SPECT, but the figure dropped to
33% with infusion of abciximab, thereby providing
evidence that platelet emboli were at least partly
involved. Magnetic Resonance Imaging (MRI), on the
other hand, is able to demonstrate subendocardial
microvascular obstruction by showing regions of
hypoenhancement after contrast injection.7 Finally,
reduction in relative coronary flow velocity reserve (as
measured by intracoronary Doppler flow analysis) after
successful coronary intervention has been observed, and
has been related to microvascular obstruction.8,9
Abnormal levels of myocardial injury markers
represent the sequelae (when other confounding factors
like acute closure during the procedure or jailing of sidebranch are absent), and also serve as circumstantial
evidence for occurrence of microvascular obstruction
during PCI. In a study by Hong et al10 recording successful,

TMP Grade 1
Stain present. Blush
persists on next
injection

TMP Grade 0
No or minimal
blush

Figure 1. TIMI Myocardial Perfusion (TMP) Grades (Graphics supplied by Medtronic Inc.).
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angiographically and clinically uncomplicated PCI in
over 700 patients with saphenous vein graft (SVG)
lesions, raised creatine kinase-MB fraction (CK-MB)
levels, defined as levels above upper normal limit, were
detected in 38.5% of patients. In a recent study which
measured serum troponin T and I levels after successful
uncomplicated elective PCI in native coronary arteries,
up to 14% of patients had raised troponin T or I levels
in absence of side-branch occlusion.11 More evidence
to suggest microembolization during PCI comes from
the observation of a higher incidence of microvascular
obstruction associated with more aggressive coronary
intervention. Directional atherectomy, for instance, was
the strongest correlate of post-procedure CK-MB
elevation in a series of patients who underwent
successful PCI (odds ratio 4.1 when compared to balloon
angioplasty).12 The paradoxical finding of a decrease in
TIMI 3 flow in patients after stenting as compared to
balloon angioplasty in the Primary Angioplasty in
Myocardial Infarction (PAMI) trial lends more support
to the occurrence of microembolization.13

Impact of Microvascular Obstruction
on Outcomes Post-PCI
It is well known that occurrence of no-reflow
during PCI is associated with higher incidence of major
adverse cardiac events (MACE). In a study addressing
this issue, the incidences of non-Q myocardial infarction
and in-hospital mortality were reported as 31% and 15%
respectively.14 Even when epicardial flow is preserved,
the occurrence of microvascular obstruction will lead
to a worse outcome. In a study which recruited patients
with normal or mildly raised (<2 times upper limit of
normal) creatine kinase after successful PCI,
Abdelmeguid et al12 showed that the subgroups with
elevated CK-MB carried a higher incidence of MACE
over a median follow-up period of 3 years. Hong et al10
in the study on SVG interventions showed that the
1-year mortality rate in patients with post-procedure
CK-MB 1-5 times upper limit of normal and those with
CK-MB more than 5 times normal were, respectively,
at least 2 times and 4 times higher than patients with
normal CK-MB levels. In another study, Stone et al15
discovered that only 29.4% of patients who had TIMI 3
flow in the infarct-related artery after primary
angioplasty achieved a TMP Grade of 3. More
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importantly, the 1-year mortality rates in this group of
patients were closely correlated to the TMP Grades:
6.8% for TMP Grade 3; 13.2% for TMP Grade 2; and
up to 18.3% for TMP Grade 0/1.

Distal Protection for PCI
Distal Protection Devices
It is therefore reasonable to hypothesize that
protecting distal vessels from particulate embolization
can improve immediate and long-term outcome after
PCI. Different distal protection devices have been
designed. As of today, they fall into one of two
categories: a) distal occlusion balloon on a wire; any
particulate debris within the column of occluded blood
will be aspirated after intervention on target lesion; and
b) filter that can be deployed distal to target lesion,
trapping any particulate debris; the filter with the
entrapped debris are then retrieved with a capture sheath.
The former, as exemplified by the GuardWire Plus
System (Medtronic®) (Figure 2), has the advantages
of having a low crossing profile and completeness of
debris retrieval, but vessel occlusion is inevitable during
the procedure. The latter, as exemplified by the
AngioGuard Emboli Capture Guidewire (Cordis®)
(Figure 3) and the EPI FilterWire (Boston Scientific®)
(Figure 4) have the advantages of allowing continued
blood flow during the procedure, but suffer from having
a larger crossing profile (4.0F or more) and uncertainties
in offering complete protection or retrieval of entrapped
particulates.

Figure 2. The GuardWire Plus System (Medtronic®).
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patients, an improvement in TIMI 3 flow from 0% to
96% of patients was noted post-intervention using the
same GuardWire System,18 with 54.5% of patients who
had TIMI 3 flow achieving TMP Grade 3. Though
randomized comparison was not available, this 54.5%
of TMP Grade 3 was a significant improvement over
the 18.8% figure obtained from historical trial data. In
96% of this cohort, either thrombus or atherosclerotic
materials were successfully aspirated.
Figure 3. The AngioGuard Emboli Capture
Guidewire (Cordis®).

Use of Distal Protection for Elective PCI in
Native Coronary Arteries

Figure 4. The EPI FilterWire (Boston
Scientific®).

Clinical Data on Use of Distal Protection for PCI
The value of distal protection has been/is being
tested in two high-risk areas for microembolization:
interventions in saphenous vein grafts and on culprit
lesions of acute coronary syndromes. The SAFER trial16
is the first randomized clinical trial examining the
benefit of distal protection using GuardWire System
(Medtronic®) during interventions in SVG. Over 800
patients were enrolled in the trial. The incidence of noreflow was 3.4% using distal protection versus 8.8%
without distal protection. Incidences of in-hospital
MACE and 30-day MACE were decreased by 38% and
42% respectively with the use of distal protection. In
the setting of intervention for acute ST elevation
myocardial infarction (STEMI), a multicentre registry
in Europe recorded in 37 patients an improvement in
TIMI 3 flow from 24.3% to 86.1% and improvement in
TMP Grade 3 from 2.7% to 58.8% of patients postintervention with the use of GuardWire System. 17
Similarly, in a single-centre cohort of 51 STEMI
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Slow distal flow or no-reflow does occur
occasionally in the setting of elective PCI (excluding
interventions during acute phase of acute coronary
syndromes). In a review on all elective PCI in native
coronary arteries conducted in the authors'
catheterization laboratory in year 2001, the incidence
of slow distal flow/no-reflow was up to 3% when vessels
≥3.5 mm in diameter were counted, and up to 13% in
vessels ≥4.0 mm in diameter. As from deduction and
also from observation, larger plaque burden and more
friable plaque predispose to occurrence of such adverse
phenomena. However, there is as yet little controlled
data on the use of distal protection for elective PCI in
native coronary arteries. A recent report from Grube et
al19 included the experience of using the AngioGuard
Emboli Capture Guidewire (Cordis®) for distal
protection in 15 native coronary lesions. Particles
retrieved from the filters were sent for histochemical
staining, and the study constitutes "the first direct
evidence that embolization of arterial plaque
components occurs routinely during native coronary
artery interventions".

Local Registry on Use of Distal Protection for
Elective PCI in Native Coronaries
In view of the potential value of distal protection
for elective PCI in native coronaries, a registry on the
use of GuardWire Plus System (an improved version
of the original GuardWire System) has been set up in
the authors' hospital. Lesions included are those within
large native coronary arteries (≥3.5 mm), or lesions with
heavy plaque load/complex morphology/overlying
thrombus in coronary arteries ≥3.0 mm. Exclusion
criteria are: a) the presence of significant (≥1.5 mm)
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side-branch between the target lesion and potential
location of distal protection balloon on the GuardWire
(as otherwise most of the dislodged particulates may
embolize down the side-branch); b) diameter of distal
vessel segment where protection balloon would be
inflated is <3.0 mm; c) planned use of adjunctive devices
other than coronary stents, which would lengthen the
procedure and also the occlusion time; and d) anticipated
difficult stenting procedure (e.g. proximal calcified
segment or excessive proximal tortuosity), as the
protection balloon is usually only positioned 20-40 mm
distal to the lesion, and support from the GuardWire is
not as good as ordinary coronary wires. The first three
exclusion criteria are specific to the GuardWire Plus
System, and serve to illustrate that each protection
system available in market bears its own characteristics
and limitations. Two or three operators co-operated in
using the system. Basically the procedure can be divided
into 4 parts (Figure 5): a) passing the GuardWire across
the lesion and inflating the distal protection balloon; b)
performing intervention on the lesion as is required; c)
aspirating any particulate debris which may be present
in the column of occluded blood; and d) deflating the
distal protection balloon. In cases of tight lesions or in

A

totally occluded vessels, an ordinary coronary guidewire
may be used to cross the lesion first (as "buddy" wire),
with or without gentle predilatation with a small
diameter balloon to allow subsequent passage of the
GuardWire. Three different strategies could be
employed for target lesion intervention, depending on
coronary anatomy and expected patient's tolerance on
vessel occlusion during distal protection: a) direct
stenting; b) balloon angioplasty followed by an interim
period of rest before stenting (referred here as balloonrest-stent); c) combined balloon angioplasty and stenting
(balloon+stent) without interruption.
So far, distal protection for elective PCI in native
coronaries has been performed for 20 lesions in 17
patients (Table 1). Majority of the lesions were in RCA,
as expected because of the large size of this vessel often
encountered (Table 2).
Predilatation for initial passage of the GuardWire
was required only in 3 lesions. In fact, with more
experience in manipulating the GuardWire and in the
presence of good guiding catheter support, it is possible
to pass it through critical lesions without the need for
predilatation. Direct stenting was performed on
11 lesions; balloon-rest-stent on 7 lesions; and

B

C

D

Figure 5. Use of the GuardWire Plus System in a SVG is illustrated. (A) Crossing the lesion with the GuardWire. (B) Performing
intervention on target lesion while distal protection balloon is inflated. (C) Aspirating particulate debris through the aspiration
catheter. (D) Deflating the distal protection balloon.
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Table 1. Patients undergoing distal protection for
elective PCI
Total no.
M:F ratio
Mean age (yrs)
Indication for PCI
Stable angina
Stabilized after recent ACS

17
14:3
65.9±11.7
10
7

Table 2. Lesion characteristics
Vessel
RCA
LCx
LAD
Mean vessel size (mm)
Lesion type
A
B1
B2
C
Mean % stenosis

15
3
2
3.56±0.36
3
11
11
6
87.4±9.6

balloon+stent on 2 lesions. Mean vessel occlusion time
was 181 seconds for stenting in direct stenting and
balloon-rest-stent; 182 seconds for balloon angioplasty
during balloon-rest-stent; and 354 seconds for
balloon+stent. There is definitely a learning curve in
using the system. The mean occlusion time for stenting
in the last 5 lesions, for instance, has dropped to 146

seconds. The incidence of chest pain during distal
protection occurred in about half of patients, bradycardia
and BP drop (>20 mmHg from baseline) in around 60%
and 50% respectively; and ST segment changes in about
90%. All these symptom and changes disappeared on
relief of the vessel occlusion. Distal protection was
successfully performed for all lesions. TIMI 3 flow and
TMP Grade 3 were noted in every case. Amount of
plaque debris retrieved was recorded in a semiquantitative manner: small, moderate, and large. In
around two-thirds of instances, the amount retrieved
was either moderate or large (Figure 6). In none of the
cases was the yield negative. Problems encountered
were: one dissection at site of distal protection balloon
caused by over-sizing, handled by stenting; one incident
of initial difficulty in retracting the GuardWire due to
the protection balloon impinging on stent struts; and
one incident of non-deflating protection balloon,
handled by cutting the GuardWire. The first two
problems could have been avoided by more careful use,
while the last problem is reportedly rare according to
manufacturer. There was no in-hospital MACE related
to the use of distal protection. It thus appears that distal
protection using GuardWire Plus System for elective
PCI in native coronaries is a feasible option. The
successful retrieval in virtually all cases of particulate
debris which would otherwise have embolized down
the distal (micro) vasculature reflected the system's
efficacy in providing myocardial protection. Indeed, the
system has probably avoided several incidents of
adverse slow flow/no-reflow phenomenon, judging

Figure 6. Plaque debris retrieved.
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from the large size of the debris retrieved in some cases.
Whether these benefits would transcribe into better
clinical outcome would require confirmation by
randomized studies. On the other hand, there is
definitely a learning curve in the use of the device.
Operators are expected to encounter problems in their
early experience, and should be prepared to overcome
them if they do occur. In fact, with careful use and
as experience grows, most problems can be avoided.
It should be emphasized, however, that as the benefitrisk ratio is comparatively lower in the setting
of elective PCI than in PCI for acute coronary
syndromes, proper case selection, as well as
acquaintance with and proper use of the system are
important issues.

Conclusion
Evidences are now growing in support for distal
protection during PCI in native coronary arteries. Wellcontrolled randomized studies may eventually confirm
its clinical value, just as in the case of intervention in
saphenous vein grafts, especially in the area of primary
angioplasty for STEMI. In the setting of elective PCI
in native coronaries, further studies are required
to identify lesions that are prone to distal
microembolization in order to justify its use. With distal
protection devices becoming user-friendlier, they may
one day turn into a frequently used gadget that will help
prevent adverse consequences secondary to particulate
embolization that cannot be effectively prevented or
handled by pharmacological means.
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